Literature DB >> 33425393

Human epidermal growth factor receptor 2 (HER2) and the future of bladder carcinoma.

Julien Sarkis1, Marwan Alkassis2, Joy Assaf3.   

Abstract

Entities:  

Year:  2020        PMID： 33425393      PMCID： PMC7755410          DOI： 10.1080/2090598X.2020.1835439

Source DB:  PubMed          Journal:  Arab J Urol        ISSN： 2090-598X


× No keyword cloud information.
  9 in total

1.  Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.

Authors:  Stéphane Oudard; Stéphane Culine; Yann Vano; François Goldwasser; Christine Théodore; Thierry Nguyen; Eric Voog; Eugeniu Banu; Annick Vieillefond; Franck Priou; Gaël Deplanque; Gwenaëlle Gravis; Alain Ravaud; Jean Michel Vannetzel; Jean-Pascal Machiels; Xavier Muracciole; Marie-France Pichon; Jacques-Olivier Bay; Reza Elaidi; Corine Teghom; François Radvanyi; Philippe Beuzeboc
Journal:  Eur J Cancer       Date:  2014-11-15       Impact factor: 9.162

2.  A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.

Authors:  Christian Wülfing; Jean-Pascal H Machiels; Dirk J Richel; Marc-Oliver Grimm; Uwe Treiber; Marco R De Groot; Philippe Beuzeboc; Roma Parikh; Frank Pétavy; Iman A El-Hariry
Journal:  Cancer       Date:  2009-07-01       Impact factor: 6.860

3.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Authors:  H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

4.  Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.

Authors:  Andrea Necchi; Andrea Anichini; Daniele Raggi; Alberto Briganti; Simona Massa; Roberta Lucianò; Maurizio Colecchia; Patrizia Giannatempo; Roberta Mortarini; Marco Bianchi; Elena Farè; Francesco Monopoli; Renzo Colombo; Andrea Gallina; Andrea Salonia; Antonella Messina; Siraj M Ali; Russell Madison; Jeffrey S Ross; Jon H Chung; Roberto Salvioni; Luigi Mariani; Francesco Montorsi
Journal:  J Clin Oncol       Date:  2018-10-20       Impact factor: 44.544

5.  Human epidermal growth factor receptor 2 (HER2) gene amplification in non-muscle invasive urothelial bladder cancers: Identification of patients for targeted therapy.

Authors:  Vinita Agrawal; Niharika Bharti; Rakesh Pandey
Journal:  Arab J Urol       Date:  2020-09-02

6.  The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette-Guérin immunotherapy: Current status.

Authors:  Łukasz Nowak; Wojciech Krajewski; Adrian Poterek; Anna Śliwa; Romuald Zdrojowy
Journal:  Arab J Urol       Date:  2020-07-16

7.  The prognostic significance of p53, p63 and her2 expression in non-muscle-invasive bladder cancer in relation to treatment with bacille Calmette-Guerin.

Authors:  Raafat Hegazy; Mostafa Kamel; Emad A Salem; Neveen A Salem; Amr Fawzy; Ahmed Sakr; Ola El-Farargy; Nashwa Nawar; Ahmed El-Atar; Ashraf M S Shahin; Abdelmonem Hegazy
Journal:  Arab J Urol       Date:  2015-07-17

8.  Human epidermal growth factor receptor 2/neu overexpression in urothelial carcinoma of the bladder and its prognostic significance: Is it worth hype?

Authors:  Santosh Kumar; Omprakash Prajapati; Kim Vaiphei; Kalpesh Mahesh Parmar; A S Sriharsha; S K Singh
Journal:  South Asian J Cancer       Date:  2015 Jul-Sep

Review 9.  Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives.

Authors:  Mikołaj Wołącewicz; Rafał Hrynkiewicz; Ewelina Grywalska; Tomasz Suchojad; Tomasz Leksowski; Jacek Roliński; Paulina Niedźwiedzka-Rystwej
Journal:  Cancers (Basel)       Date:  2020-05-07       Impact factor: 6.639
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.